

Table 11.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Heart Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	2,293	2,348	2,188	2,199	2,202	2,155	2,057	2,015	2,125	2,193
Tx with Antirejection Treatments	872	979	916	901	849	803	656	533	533	487
Antibodies										
Any in Category	19.3%	21.2%	17.7%	16.3%	15.5%	17.4%	18.4%	15.6%	18.0%	19.3%
Atgam/NRATG/NRATS	7.9%	7.3%	6.3%	4.6%	3.9%	4.0%	4.6%	2.6%	2.4%	3.7%
OKT3	13.1%	14.9%	7.4%	5.1%	5.8%	6.8%	4.1%	3.2%	3.4%	3.7%
Thymoglobulin	0.1%	0.2%	2.0%	3.8%	4.9%	6.4%	7.5%	8.6%	9.4%	11.3%
Zenapax	0.1%	0.8%	2.5%	3.0%	2.5%	1.5%	2.0%	1.5%	3.6%	1.6%
Simulect	0.0%	0.1%	0.9%	2.0%	0.4%	0.4%	1.4%	0.6%	0.8%	0.4%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	0.2%
Corticosteroids										
Any in Category	88.6%	87.9%	91.3%	92.3%	92.7%	92.2%	92.5%	91.4%	90.8%	90.3%
Steroids	88.6%	87.9%	91.3%	92.3%	92.7%	92.2%	92.5%	91.4%	90.8%	90.3%
Antimetabolites										
Any in Category	7.6%	6.5%	4.6%	4.4%	2.0%	3.0%	3.5%	1.7%	2.3%	1.8%
Cytosan	3.6%	2.5%	2.1%	1.7%	0.5%	0.9%	1.7%	1.3%	1.3%	1.6%
Methotrexate	4.1%	4.3%	2.6%	2.8%	1.5%	2.1%	1.8%	0.4%	0.9%	0.2%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.